GlaxoSmithKline Czech Republic made a net profit of CZK 65.4 mil in 2017, up 72.0% when compared to the last year. Total sales reached CZK 2,897 mil, which is down 14.6% when compared to the previous year.
Historically, the company’s net profit reached an all time high of CZK 240 mil in 2011 and an all time low of CZK -7.67 mil in 2006.
In terms of sales, GlaxoSmithKline Czech Republic reached an all time high of CZK 6,186 mil in 2009 and an all time low of CZK 2,897 mil in 2017.
GlaxoSmithKline Czech Republic's net profit has grown -16.8% a year on average in the last five years while sales have increased by -12.8% a year since 2012.
The firm generated its shareholders an average return on invested capital of 6.67% in the last five years.
As far as GlaxoSmithKline Czech Republic's peers are concerned, Bayer Czech Republic posted a net profit and sales of CZK 106 mil and CZK 4,180 mil in 2017 and Amgen Czech Republic generated a net profit of CZK 37.8 mil (with sales of CZK 417 mil).
|Amgen Czech Republic||CZK mil||46.2||28.3||28.7||40.5||35.8|
|Bayer Czech Republic||CZK mil||166||83.4||96.2||107||123|
|GlaxoSmithKline Czech Republic||CZK mil||240||164||127||87.7||125|
|Merck Czech Republic||CZK mil||49.3||63.4||27.4||34.9||68.6|
|Novartis Czech Republic||CZK mil||41.7||50.0||52.3||82.2||82.7|
|Pfizer Czech Republic||CZK mil||231||48.1||144||134||75.4|
|Roche Czech Republic||CZK mil||50.5||38.7||135||94.9||51.0||...|
|Sanofi-Aventis Czech Republic||CZK mil||55.1||45.2||65.2||1.19||58.6|
|Servier Czech Republic||CZK mil||...||...||12.8||13.6||13.6||15.9|